aTyr Pharma reports year-end 2024 cash of $75.1M; Phase 3 topline data due Q3 2025

aTYR PHARMA INC

Cash, equivalents and investments $75.1M as of Dec 31, 2024; raised ~$18.8M via ATM after quarter-end.
Phase 3 EFZO-FIT enrollment complete (268 patients); topline pulmonary sarcoidosis data expected Q3 2025.
Fourth positive DSMB review; FDA meeting finalized SAP on steroid reduction endpoint.
Phase 2 EFZO-CONNECT interim data for scleroderma-ILD expected Q2 2025.
R&D expenses $54.4M, G&A $13.8M for FY2024; cash runway extends one year past Phase 3 readout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.